Published in Nature on October 04, 1969
Lymphocyte-mediated modification of blood-derived macrophage function in vitro; inhibition of growth of intracellular mycobacteria with lymphokines. Clin Exp Immunol (1971) 3.74
'Lymphokines': molecular mediators of cellular immune responses in animals and man. Proc R Soc Med (1970) 2.13
In vitro studies of cell-mediated immunity. I. Induction of lymphocyte transformation by a soluble "mitogenic" factor derived from interaction of sensitized guinea-pig lymphoid cells with specific antigen. Immunology (1970) 1.60
Epidermal T lymphocytes and dendritic cells in chronic plaque psoriasis: the effects of PUVA treatment. Clin Exp Immunol (1985) 1.29
The production of lymphocyte mitogenic factor and migration-inhibition factor by antigen-stimulated lymphocytes of subjects with grass pollen allergy. Clin Exp Immunol (1971) 1.09
Lymphocyte transformation in vitro. IV. Recruitment in antigen-stimulated cultures. Clin Exp Immunol (1971) 1.08
A study of histamine release from human basophils and lung mast cells by products of lymphocyte stimulation. Agents Actions (1983) 1.06
Anti-TNF therapy: past, present and future. Int Immunol (2014) 1.05
Effects of acetaminophen on normal human peripheral blood lymphocytes: enhancement of mitogen- and antigen-stimulated incorporation of tritiated thymidine. Clin Exp Immunol (1979) 0.96
Treatment of chronic mucocutaneous moniliasis by immunologic reconstitution. Clin Exp Immunol (1971) 0.94
Transfer factor and other mediators of cellular immunity. Am J Pathol (1970) 0.81
Production of mitogenic factor by concanavalin A stimulated lymphocytes. Clin Exp Immunol (1972) 0.81
Development of antibodies during long-term therapy with corticotrophin in rheumatoid arthritis. I. Porcine ACTH. Ann Rheum Dis (1971) 0.80
Antigen release from insoluble polymer complexes by lymphocyte cell suspensions. Clin Exp Immunol (1971) 0.75
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Role of cytokines in rheumatoid arthritis. Annu Rev Immunol (1996) 10.22
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum (2000) 6.46
"Lymphokines": non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature (1969) 6.42
Rheumatoid arthritis. Cell (1996) 6.01
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol (2001) 5.59
Immunological phenomena in leprosy and related diseases. Adv Immunol (1971) 5.55
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A (1992) 5.07
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum (1993) 5.05
Immunity in cutaneous leishmaniasis of the guinea-pig. Clin Exp Immunol (1970) 4.50
A micro-method for peripheral leucocyte migration in tuberculin sensitivity. J Clin Pathol (1971) 3.45
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum (1991) 3.35
Delayed hypersensitivity in the guinea-pig to a protein-hapten conjugate and its relationship to in vitro transformation of lymph node, spleen, thymus and peripheral blood lymphocytes. Immunology (1967) 3.33
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Immunosuppression in children with malaria. Lancet (1972) 3.11
Experimental cutaneous leishmaniasis. 3. Effects of thymectomy on the course of infection of CBA mice with Leishmania tropica. Clin Exp Immunol (1972) 3.08
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. Arthritis Rheum (2000) 3.06
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum (1996) 2.96
Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 2.90
Diffuse cutaneous leishmaniasis in Ethiopia. I. The clinical and histological features of the disease. Trans R Soc Trop Med Hyg (1969) 2.78
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Allergic complications of meningococcal disease. II. Immunological investigations. Br Med J (1973) 2.61
Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg (1983) 2.57
Malaria at Christmas: risks of prophylaxis versus risks of malaria. BMJ (1998) 2.48
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis (2008) 2.45
Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 2.41
Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res (2000) 2.37
TNF alpha--a pivotal role in rheumatoid arthritis? Br J Rheumatol (1992) 2.34
Fever as the presenting complaint of travellers returning from the tropics. QJM (1995) 2.34
Diffuse cutaneous leishmaniasis in Ethiopia. 3. Immunological studies. IV. Pathogenesis of diffuse cutaneous leishmaniasis. Trans R Soc Trop Med Hyg (1970) 2.32
Lesions of schistosomiasis mimicking warts on the vulva. BMJ (1993) 2.25
Measurement of DNA antibodies by double antibody precipitation. Ann Rheum Dis (1973) 2.21
Allertic complications of meningococcal disease. I. Clinical aspects. Br Med J (1973) 2.20
Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse. Clin Exp Immunol (1976) 2.20
Interleukin 1 in Crohn's disease. Clin Exp Immunol (1987) 2.18
Experimental cutaneous leishmaniasis. II. Effects of immunosuppression and antigenic competition on the course of infection with Leishmania enriettii in the guinea-pig. Clin Exp Immunol (1972) 2.15
Tissue-specific antigens. Adv Immunol (1966) 2.15
'Lymphokines': molecular mediators of cellular immune responses in animals and man. Proc R Soc Med (1970) 2.13
Disappearance of immunoglobulin and complement from the Arthus reaction and its relevance to studies of vasculitis in man. Br J Dermatol (1971) 2.11
The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. Q J Med (1979) 2.07
The role of the macrophage in delayed hypersensitivity. Br Med Bull (1967) 2.07
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol (1988) 2.06
Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin Exp Immunol (1998) 2.03
The clinical significance of mediators of cellular immunity. Clin Allergy (1971) 2.03
Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. Br Med J (1978) 2.01
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol (1990) 2.01
Immunosuppression in Kenyan visceral leishmaniasis. Clin Exp Immunol (1983) 2.00
A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis Rheum (1985) 1.99
Adverse reactions in expatriates treated with ivermectin. Lancet (1990) 1.98
Role of lymphocyte activation products (LAP) in cell-mediated immunity. II. Effects of lymphocyte activation products on lymph node architecture and evidence for peripheral release of LAP following antigenic stimulation. Clin Exp Immunol (1972) 1.94
Cell-mediated immunity during natural measles infection. J Clin Invest (1978) 1.93
Interleukin-10 inhibition of the progression of established collagen-induced arthritis. Arthritis Rheum (1996) 1.87
Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha. Eur J Immunol (1991) 1.87
Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet (1991) 1.87
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest (1994) 1.81
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum (1998) 1.79
Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis (1996) 1.75
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
Purification and characterization of the Sjögren's syndrome A and B antigens. Clin Exp Immunol (1983) 1.73
Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A (1989) 1.72
Anti-retinal autoimmunity and circulating immune complexes in patients with retinal vasculitis. Lancet (1982) 1.68
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis (1975) 1.67
The effect of prolonged treatment with antilymphocyte serum on the course of infections with BCG and Leishmania enriettii in the guinea-pig. J Pathol (1971) 1.66
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. Ann Rheum Dis (1986) 1.66
Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. Ann Rheum Dis (1980) 1.65
Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today (1993) 1.64
Visceral leishmaniasis in HIV infection and AIDS: clinical features and response to therapy. Q J Med (1990) 1.61
In vitro studies of cell-mediated immunity. I. Induction of lymphocyte transformation by a soluble "mitogenic" factor derived from interaction of sensitized guinea-pig lymphoid cells with specific antigen. Immunology (1970) 1.60
Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ (1998) 1.60
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. Br J Rheumatol (1992) 1.59
Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol (1997) 1.57
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum (2004) 1.56
Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis (1976) 1.56
Murine lupus monoclonal antibodies define five epitopes on two different Sm polypeptides. Immunology (1986) 1.54
Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis. Adv Immunol (1997) 1.53
Serological and immunogenetic markers of extraglandular primary Sjögren's syndrome. Br J Rheumatol (1993) 1.53
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum (1992) 1.53
DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol (1997) 1.52
Role of lymphocyte activation products (LAP) in cell-mediated immunity. I. Preparation and partial purification of guinea-pig LAP. Clin Exp Immunol (1972) 1.51
Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection. Arthritis Rheum (1981) 1.49
Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis. Arthritis Rheum (2000) 1.49
Quantitation and detection of isotypes of anti-SS-B antibodies by ELISA and Farr assays using affinity purified antigens. An approach to the investigation of Sjögren's syndrome and systemic lupus erythematosus. Arthritis Rheum (1983) 1.48
Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw (1996) 1.47
Infliximab in active early rheumatoid arthritis. Ann Rheum Dis (2004) 1.47
Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. Clin Exp Immunol (1980) 1.47